Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 3/20 | 0.38 |
| ▸ | HEXA | P06865 | 1/20 | 0.37 |
| ▸ | HEXB | P07686 | 1/20 | 0.37 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 14/20 | 0.35 |
| ▸ | RXRA | P19793 | 2/20 | 0.35 |
| ▸ | SIK1 | P57059 | 1/20 | 0.35 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.35 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7868927 | 1.00 | HTT (0.38) | HTTHASPINHEXAHEXBDYRK2 | |
| SCHEMBL7863446 | 0.99 | HTT (0.39) | HTTHASPINHEXAHEXBDYRK2 | |
| SCHEMBL7868806 | 0.95 | HTT (0.40) | HTTHASPINHEXAHEXBDYRK2 | |
| SCHEMBL7871622 | 0.82 | HTT (0.36) | HTT | |
| SCHEMBL7863443 | 0.78 | FAAH (0.38) | HTT | |
| SCHEMBL7871635 | 0.78 | EPHX1 (0.37) | HTTTDP1 | |
| SCHEMBL7870372 | 0.78 | MEN1 (0.38) | HTT | |
| Hydrochloric Acid SCHEMBL7870301 | 0.78 | TDP1 (0.38) | HTTTDP1 | |
| SCHEMBL7872390 | 0.78 | TDP1 (0.32) | HTTTDP1 | |
| SCHEMBL7871580 | 0.78 | TDP1 (0.32) | HTTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | TAKATANI MUNEO (JP) | 2001-12-13 | — | — | US | disclosed |
| US-6251905-B1 | Tricyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-06-26 | — | — | US | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051631-A1 | Tricyclic compounds, their production and use | PDGFA, HGF, REN | HTT 710/4885HASPIN 3077/4885HEXA 1138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.